Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 2
1994 1
1995 1
1998 1
1999 1
2000 1
2001 1
2002 1
2004 1
2005 2
2006 2
2007 1
2008 2
2009 2
2010 1
2011 1
2013 3
2014 3
2015 4
2016 3
2018 4
2019 3
2020 3
2021 5
2022 4
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
COVID pandemic and denosumab adherence.
Minisola S, Cipriani C, Vigna E, Sonato C, Colangelo L, Monti F, Pepe J. Minisola S, et al. Among authors: vigna e. Osteoporos Int. 2022 Apr;33(4):943-944. doi: 10.1007/s00198-021-06274-x. Epub 2022 Jan 23. Osteoporos Int. 2022. PMID: 35066593 Free PMC article. No abstract available.
Update on the safety and efficacy of teriparatide in the treatment of osteoporosis.
Minisola S, Cipriani C, Grotta GD, Colangelo L, Occhiuto M, Biondi P, Sonato C, Vigna E, Cilli M, Pepe J. Minisola S, et al. Among authors: vigna e. Ther Adv Musculoskelet Dis. 2019 Oct 5;11:1759720X19877994. doi: 10.1177/1759720X19877994. eCollection 2019. Ther Adv Musculoskelet Dis. 2019. PMID: 31632472 Free PMC article. Review.
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.
Rotolo R, Leuci V, Donini C, Galvagno F, Massa A, De Santis MC, Peirone S, Medico G, Sanlorenzo M, Vujic I, Gammaitoni L, Basiricò M, Righi L, Riganti C, Salaroglio IC, Napoli F, Tabbò F, Mariniello A, Vigna E, Modica C, D'Ambrosio L, Grignani G, Taulli R, Hirsch E, Cereda M, Aglietta M, Scagliotti GV, Novello S, Bironzo P, Sangiolo D. Rotolo R, et al. Among authors: vigna e. Clin Cancer Res. 2023 Feb 1;29(3):621-634. doi: 10.1158/1078-0432.CCR-22-0761. Clin Cancer Res. 2023. PMID: 36165915 Free PMC article.
Cisplatin significantly increased PD-1 expression on chemo-surviving NSCLC cells (2.5-fold P = 0.0014), while the sequential treatment with anti-PD-1 Ab impaired their recovery after chemotherapy. ...PD-1 expression was enhanced in NSCLC stem-like pneumospheres (P & …
Cisplatin significantly increased PD-1 expression on chemo-surviving NSCLC cells (2.5-fold P = 0.0014), while the sequential treatmen …
A receptor-antibody hybrid hampering MET-driven metastatic spread.
Modica C, Basilico C, Chiriaco C, Borrelli N, Comoglio PM, Vigna E. Modica C, et al. Among authors: vigna e. J Exp Clin Cancer Res. 2021 Jan 14;40(1):32. doi: 10.1186/s13046-020-01822-5. J Exp Clin Cancer Res. 2021. PMID: 33446252 Free PMC article.
Replenishment of vitamin D status: theoretical and practical considerations.
Minisola S, Pepe J, Donato P, Vigna E, Occhiuto M, Ferrone F, Biamonte F, Cecchetti V, Danese VC, Sonato C, BIondi P, Colangelo L, Cipriani C. Minisola S, et al. Among authors: vigna e. Hormones (Athens). 2019 Mar;18(1):3-5. doi: 10.1007/s42000-018-0040-6. Epub 2018 Jun 12. Hormones (Athens). 2019. PMID: 29949127 No abstract available.
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.
Leuci V, Casucci GM, Grignani G, Rotolo R, Rossotti U, Vigna E, Gammaitoni L, Mesiano G, Fiorino E, Donini C, Pisacane A, Ambrosio LD, Pignochino Y, Aglietta M, Bondanza A, Sangiolo D. Leuci V, et al. Among authors: vigna e. Oncoimmunology. 2018 Feb 15;7(5):e1423167. doi: 10.1080/2162402X.2017.1423167. eCollection 2018. Oncoimmunology. 2018. PMID: 29721373 Free PMC article.
The killing activity was significantly higher compared with unmodified CIK, especially at low effector/target (E/T) ratios: 98% vs 82% (E/T = 10:1) and 68% vs 26% (1:4), (p<0.0001). Specificity of tumor killing was confirmed by blocking with anti-CD44v6 antibody. ...CAR …
The killing activity was significantly higher compared with unmodified CIK, especially at low effector/target (E/T) ratios: 98% vs 82% (E/T …
55 results